Condition (MeSH)
Miller Fisher Syndrome
ClinicalTrials.gov lists 2 trials for Miller Fisher Syndrome or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
2 of the 2 trials are tagged with Miller Fisher Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Miller Fisher Syndrome trials start? (2)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2018 | 1 |
| 2012 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 2 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Miller Fisher Syndrome trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Not applicable | 1 |
| Observational | 1 |
How many Miller Fisher Syndrome trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which publications cover Miller Fisher Syndrome? (5)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Atypical case of Miller-Fisher syndrome presenting with severe dysphagia and weight loss. | BMJ case reports | 2020 | Yes |
| Miller Fisher syndrome with positivity of anti-GAD antibodies. | Clinical neurology and neurosurgery | 2013 | Yes |
| Antiganglioside antibodies in Guillain-Barré syndrome and its related conditions. | Expert review of neurotherapeutics | 2011 | Yes |
| Intravenous immunoglobulin therapy for Miller Fisher syndrome. | Neurology | 2007 | Yes |
| Autoimmune peripheral neuropathies. | Clinica chimica acta; international journal of clinical chemistry | 2015 | No |
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Miller Fisher syndrome | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Miller Fisher syndrome | Annual incidence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Miller Fisher syndrome | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Miller Fisher syndrome | Annual incidence | 1-9 / 1 000 000 | Europe | Not stated | Unspecified |
| Miller Fisher syndrome | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Unspecified |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Miller Fisher syndrome | 98919 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Miller Fisher syndrome | 98919 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.